Taiwan Study Examines Pregnancy Outcomes After Accidental GLP-1 Drug Exposure Around Conception

A nationwide Taiwan cohort study evaluated whether unintentional GLP-1 drug exposure around conception is associated with adverse pregnancy outcomes in women with type 2 diabetes.

Chou, Yi-Chang et al.·Diabetes·2026·
RPEP-150392026RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

The nationwide cohort study assessed associations between periconceptional GLP-1 RA exposure and adverse pregnancy outcomes in women with pregestational T2DM compared to insulin users.

Key Numbers

How They Did This

Nationwide cohort study linking Taiwan's Birth Certificate Application and National Health Insurance claims 2013-2022; periconceptional GLP-1 RA exposure vs insulin.

Why This Research Matters

Millions of reproductive-age women now take GLP-1 drugs. Understanding pregnancy risks from accidental exposure around conception is critical for counseling and prescribing guidelines.

The Bigger Picture

This addresses one of the most urgent safety questions in the GLP-1 drug era — what happens when women become pregnant while taking these medications, as millions of reproductive-age women now use them.

What This Study Doesn't Tell Us

Observational database study; exposure defined by dispensing, not actual use; confounding by diabetes severity; Taiwan population may differ from others.

Questions This Raises

  • ?Should all women of reproductive age on GLP-1 drugs use reliable contraception?
  • ?How long before conception should GLP-1 drugs be discontinued for safety?

Trust & Context

Key Stat:
Nationwide pregnancy safety data Taiwan cohort assesses GLP-1 RA periconceptional exposure in diabetic mothers
Evidence Grade:
Nationwide retrospective cohort — large population-based study but observational design limits causal inference.
Study Age:
Published in 2026, addressing an increasingly urgent reproductive safety question.
Original Title:
Unintentional periconceptional exposure to glucagon-like peptide-1 receptor agonists and adverse pregnancy outcomes: A nationwide cohort study in Taiwan.
Published In:
Diabetes, obesity & metabolism, 28(2), 1420-1430 (2026)
Database ID:
RPEP-15039

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Is it safe to get pregnant while taking a GLP-1 drug?

GLP-1 drugs are not recommended during pregnancy, and this study examines what happens when women are accidentally exposed around conception. Current guidance recommends stopping GLP-1 drugs at least 2 months before planned pregnancy.

Why is this study important now?

With millions of reproductive-age women now using GLP-1 drugs for diabetes or weight loss, unintended pregnancies while on these medications are increasingly common. Understanding the risks is essential for patient safety.

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-15039·https://rethinkpeptides.com/research/RPEP-15039

APA

Chou, Yi-Chang; Weng, Shih-Han; Cheng, Feng-Shiang; Tseng, Chih-Hao; Hu, Hsiao-Yun; Liu, Chieh-Hsing. (2026). Unintentional periconceptional exposure to glucagon-like peptide-1 receptor agonists and adverse pregnancy outcomes: A nationwide cohort study in Taiwan.. Diabetes, obesity & metabolism, 28(2), 1420-1430. https://doi.org/10.1111/dom.70334

MLA

Chou, Yi-Chang, et al. "Unintentional periconceptional exposure to glucagon-like peptide-1 receptor agonists and adverse pregnancy outcomes: A nationwide cohort study in Taiwan.." Diabetes, 2026. https://doi.org/10.1111/dom.70334

RethinkPeptides

RethinkPeptides Research Database. "Unintentional periconceptional exposure to glucagon-like pep..." RPEP-15039. Retrieved from https://rethinkpeptides.com/research/chou-2026-unintentional-periconceptional-exposure-to

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.